Journal of Clinical Pharmacology

Article	Citations
Incidence of Antiseizure Medication–Induced Severe Cutaneous Adverse Reactions in Malaysia	58
	55
Pharmacokinetics of Tacrolimus in Pregnant Solid‐Organ Transplant Recipients: A Retrospective Study	43
Application of a Precision‐Dosing Model to a Real‐World Cohort of Patients on Infliximab Maintenance Therapy: Drug Usage and Cost Analysis	37
Population Pharmacokinetic and Pharmacodynamic of Atorvastatin in Chinese Lung Transplant Recipients	35
Influence of Renal Function on Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Romosozumab	32
Extrapolation of Adult Efficacy Data to Pediatric Systemic Lupus Erythematosus: Evaluating Similarities in Exposure–Response	32
The Nocebo Response in Pharmacologic Treatments of Primary Headache: A Systematic Review and Meta‐Analysis	30
	27
Meta‐Analysis of Noncompartmental Pharmacokinetic Parameters of Ertugliflozin to Evaluate Dose Proportionality and UGT1A9 Polymorphism Effect on Exposure	22
Neurological Immune‐Related Adverse Events After COVID‐19 Vaccination: A Systematic Review	22
Drug Safety in Labeling for Pediatric Drug Development and Dose Selection in Submissions to the US Food and Drug Administration	21
Evaluation of the Pharmacokinetics of Dapagliflozin in Patients With Chronic Kidney Disease With or Without Type 2 Diabetes Mellitus	21
Clinical Lactation Studies of Neuropsychiatric Medications: Clinical Pharmacology and Labeling Considerations	20
	20
	19
Protecting Mothers and Babies Through Research	19
Population Pharmacokinetics of Rivaroxaban in Real‐World Patients	18
Evaluation of the Pharmacokinetic Drug Interaction of Capmatinib With Itraconazole and Rifampicin and Potential Impact on Renal Transporters in Healthy Subjects	18
Gene‐Gene Interactions of Gemcitabine Metabolizing‐Enzyme Genes hCNT3 and WEE1 for Preventing Severe Gemcitabine‐Induced Hematological Toxicity	18
Issue Information	17
	17
The Importance of Diversity and Inclusion in Drug Development and Clinical Trial Conduct	16
	16
	16

Issue Information	15
Drug Lawsuit Advertisements and the Importance of Physician Consultation Prior to Voluntary Medication Withdrawal or Transition	15
Clinical and Pharmacological Parameters Determine Relapse During Clopidogrel Treatment of Acute Coronary Syndrome	14
Issue Information	14
Conflation of Tuskegee Study With FDA Fiduciary Responsibilities Sensationally Ignores International Law	14
Clinical Pharmacokinetics From the Beginning: A Practical Approach	14
2021 JCP Reviewer Thank You List	14
	14
Anaphylaxis to Subcutaneous Immunoglobulin in a Severe Combined Immunodeficiency Patient	13
Drugs of Abuse: How Clinical Pharmacology Brings Clarity to the Shadows	13
Issue Information	13
Issue Information	13
Issue Information	13
Issue Information	13
External Validation of Obese/Critically Ill Vancomycin Population Pharmacokinetic Models in Critically Ill Patients Who Are Obese	12
Modeling Complex Pharmacokinetics of Long‐Acting Injectable Products Using Convolution‐Based Models With Nonparametric Input Functions	12
Physiologically Based Pharmacokinetic Modeling and Allometric Scaling in Pediatric Drug Development: Where Do We Draw the Line?	12
What Is the Role of Sex‐Related Differences in the Effectiveness and Safety of Biological Drugs Used in Patients With Severe Asthma?	12
Itacitinib Population Pharmacokinetics and Exposure‐Response in Patients With Acute Graft‐Versus‐Host Disease	11
Addressing the Knowledge Gaps for Providing Optimal Drug Pharmacotherapy for the Obese	11
Exposure–Response Analyses for Belzutifan to Inform Dosing Considerations and Labeling	11
Neonatal Therapeutics: Time for a More Effective and Impactful Collaboration Between Neonatologists and Clinical Pharmacologists	11
Low Early Antifactor Xa Target Achievement Rate of Low‐Molecular‐Weight Heparin for Treating Venous Thromboembolism in Patients in Intensive Care	11
Population Pharmacokinetic‐Pharmacodynamic Modeling and Covariate Analyses of Neutropenia and Thrombocytopenia in Patients With Solid Tumors Treated With Lurbinectedin	11
The Impact of Telmisartan on Cardiometabolic Risk Factors in Hypertensive Male Siblings of Women With Polycystic Ovary Syndrome	11
Population Pharmacokinetics, Exposure–Safety, and Probability of Target Attainment Analyses for Isavuconazole in Japanese Patients With Deep‐Seated Mycoses	11
	11
Development and Verification of a Japanese Pediatric Physiologically Based Pharmacokinetic Model with Emphasis on Drugs Eliminated by Cytochrome P450 or Renal Excretion	10
Landscape and Regulatory Perspective on Oncology Drugs in Pregnancy	10
Safety, Pharmacokinetics, and Pharmacodynamics of the New Aldose Reductase Inhibitor Govorestat (AT‐007) After a Single and Multiple Doses in Participants in a Phase 1/2 Study	10
Pharmacokinetics and Safety of a Novel Extended‐Release Microsphere Formulation of Risperidone in Patients with Schizophrenia or Schizoaffective Disorder	10
Reply to: Comment: Detection of Vaccine Adverse Events Before Package Insert Revisions Using a Japanese Spontaneous Reporting System	10
Drug‐Drug Interaction between Oral Zamicastat and Continuous Epoprostenol Infusion at Steady‐State Conditions in Healthy Subjects	10
Labetalol Dosing in Pregnancy: PBPK/PD and CYP2C19 Polymorphisms	10
Clinical Characteristics of Moxifloxacin‐Related Arrhythmias and Development of a Predictive Nomogram: A Case Control Study	10
	10
Safety, Tolerability, and Pharmacokinetics of Single Doses of Exidavnemab (BAN0805), an Anti‐α‐Synuclein Antibody, in Healthy Western, Caucasian, Japanese, and Han Chinese Adults	10
Pharmacokinetics of Human Plasma‐Derived Antithrombin in Pediatric Patients Supported on Extracorporeal Membrane Oxygenation	10
Issue Information	9
Association of Vancomycin AUC/MIC and Trough Concentration With Early Clinical Response in Enterococcus or Coagulase‐Negative Staphylococcus Infection: A Prospective Study	9
Impact of Lisinopril on Cardiometabolic Risk Factors in Sisters of Women With Polycystic Ovary Syndrome	9
Vancomycin Associated Purpuric Symmetrical Drug‐Related Intertriginous and Flexural Exanthema: A Rare Association and an Uncommon Presentation	9
First‐in‐Human Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of DISC‐0974, an Anti‐Hemojuvelin Antibody, in Healthy Participants	9
	9
Pharmacokinetic Evaluation of Blonanserin Transdermal Patch: Population Analysis and Simulation of Plasma Concentration and Dopamine D2 Receptor Occupancy in Clinical Settings	9
Relative Bioavailability of Cenobamate Administered as a Crushed Tablet, Either Orally or via Nasogastric Tube, versus an Intact Whole Tablet	9
Ketamine for Refractory Chronic Migraine: An Observational Pilot Study and Metabolite Analysis	8
Effects of Triamterene in Hospitalized Patients with Heart Failure and Diuretic Resistance: A Randomized Clinical Trial	8
Do ADHD Treatments Improve Executive Behavior Beyond Core ADHD Symptoms in Adults? Evidence From Systematic Analysis of Clinical Trials	8
Issue Information	8

	8
New Variants of SARS‐CoV‐2 and Next Generation of COVID‐19 Treatments	8
Single‐ and Multiple‐Dose Pharmacokinetics of Gefapixant (MK‐7264), a P2X3 Receptor Antagonist, in Healthy Adults	8
	8
Risk of Thrombocytopenia With Platelet‐Derived Growth Factor Receptor Kinase Inhibitors in Cancer Patients: A Systematic Review and Meta‐Analysis of Phase 2/3 Randomized, Controlled Trials	8
Population Pharmacokinetics of Tenecteplase in Patients With Acute Myocardial Infarction and Application to Patients With Acute Ischemic Stroke	8
Effect Compartment Model for the Evaluation of Tolerance to Psychological Highness Following Smoking Marijuana	8
Total, Unbound, Renal, and Hepatic Clearances of Raltegravir and the Formation and Elimination Clearances of Raltegravir Glucuronide in Pregnant Women	8
Population Pharmacokinetics of Ipatasertib and Its Metabolite in Cancer Patients	8
Impact of Multiple Concomitant CYP3A Inhibitors on Venetoclax Pharmacokinetics: A PBPK and Population PK‐Informed Analysis	8
Pharmacokinetics‐Based Pediatric Dose Evaluation and Optimization Using Saliva – A Case Study	8
Drug Combination Modeling: Methods and Applications in Drug Development	8
Improving Racial and Ethnic Equity in Clinical Trials Enrolling Pregnant and Lactating Individuals	7
Effect of Renal Impairment on the Pharmacokinetics of Firsocostat, an Acetyl‐Coenzyme A Carboxylase Inhibitor, and Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor Agonist	7
Physiologically Based Pharmacokinetic Modeling to Assess the Impact of CYP2D6‐Mediated Drug‐Drug Interactions on Tramadol and O‐Desmethyltramadol Exposures via Allosteric and Competitive Inhibition	7
Sedative‐Hypnotic Agents That Impact Gamma‐Aminobutyric Acid Receptors: Focus on Flunitrazepam, Gamma‐Hydroxybutyric Acid, Phenibut, and Selank	7
Maternal–Fetal Drug Development: An Industry Perspective	7
Ceftaroline Dosage Optimized for Pediatric Patients With Renal Impairment Using Physiologically Based Pharmacokinetic Modeling	7
Potential COVID‐19 Therapeutic Agents and Vaccines: An Evidence‐Based Review	7
Thyroid Antibody Titers and Hypothalamic‐Pituitary‐Thyroid Axis Activity in Levothyroxine‐Treated Women With Autoimmune Subclinical Hypothyroidism Receiving Atorvastatin or Metformin	7
Effects of Renal Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites	7
Population Pharmacokinetics of Voriconazole and Dose Optimization in Elderly Chinese Patients	7
Breast Milk Excretion of Dinalbuphine Sebacate Injection Administered After Cesarean Section	7
Challenges in Conducting Therapeutic Trials in Pregnancy: Emphasizing Recent Lessons Learned	7
Investigation of the Differences in the Pharmacokinetics of CYP2D6 Substrates, Desipramine, and Dextromethorphan in Healthy African Subjects Carrying the Allelic Variants CYP2D6*17 and CYP2D6*29, When	7
DOAC Dosing Discordance Using Different Estimates of Kidney Function and Outcomes	7
Exploring the Knowledge Gaps in Infant Drug Exposure From Human Milk: A Clinical Pharmacology Perspective	7
Exploring Factors Affecting the Occurrence of Hypersensitivity Reactions Induced by Nonionic Iodine Contrast Media	7
Issue Information	7
Reassessing the Pediatric Dosing Recommendations for Unfractionated Heparin Using Real‐World Data: A Pharmacokinetic–Pharmacodynamic Modeling Approach	7
Pharmacokinetics (PK) of Tiragolumab in First‐in‐Human Study in Patients with Mixed Solid Tumors (GO30103)	7
Intrapulmonary Pharmacokinetic Modeling and Simulation of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Patients With Pneumonia and Healthy Subjects	6
In Vivo Activity of Intestinal P‐Glycoprotein and Hepatic Organic Anion Transporters Polypeptide in Pregnancy and Postpartum	6
Pharmacokinetics and Pharmacodynamics of Intravenous Magnesium Sulfate in Pediatric Acute Asthma Exacerbations	6
Atezolizumab Plus Bevacizumab Versus Lenvatinib for Hepatocellular Carcinoma: A Systematic Review and Meta‐Analysis	6
Implementation of Clinical Cytochrome P450 3A Genotyping for Tacrolimus Dosing in a Large Kidney Transplant Program	6
Evaluation of Drug‐Drug Interactions of Ensitrelvir, a SARS‐CoV‐2 3CL Protease Inhibitor, With Transporter Substrates Based on In Vitro and Clinical Studies	6
Use of Real‐World Data and Pharmacometric Modeling in Support of Lacosamide Dosing in Pediatric Patients Under 4 Years of Age	6
Antibody‐Mediated Rejection in Adult Liver Transplant Recipients: A Case Series and Literature Review	6
Drug‐Drug Interactions of Artemisinin‐Based Combination Therapies in Malaria Treatment: A Narrative Review of the Literature	6
Pharmacokinetic/Pharmacodynamic Parameters of Linezolid in the Epithelial Lining Fluid of Patients With Sepsis	6
Clinical Pharmacology of the Dietary Supplement Kratom (Mitragyna speciosa)	6
The Use of Pregnancy Physiologically Based Pharmacokinetic Modeling for Renally Cleared Drugs	6
Heterogeneity in the Identification of Potential Drug‐Drug Interactions in the Intensive Care Unit: A Systematic Review, Critical Appraisal, and Reporting Recommendations	6
Quetiapine‐Induced Thyroid Dysfunction: A Systematic Review	6
Embracing Uncertainties Over the Evidence of New Oral Antivirals for COVID‐19: Challenges in Pharmacoepidemiologic Research	6
Association Between the Use of Sodium‐Glucose Cotransporter‐2 Inhibitors and Drug‐Induced Acute Kidney Injury: Analysis of 2 Databases	6
Prenatal Somatic Cell Gene Therapies: Charting a Path Toward Clinical Applications (Proceedings of the CERSI‐FDA Meeting)	6
Gabapentinoid Pharmacology in the Context of Emerging Misuse Liability	6
Assessment of the Effect of Organ Impairment on the Pharmacokinetics of 2′‐MOE and Phosphorothioate Modified Antisense Oligonucleotides	6
Comparison of Clinical Effectiveness Between Ambroxol and N‐Acetylcysteine in Surgical Patients: A Retrospective Cohort Study	6
Issue Information	6
The Effects of Mannuronic Acid on IL‐1β, IL‐17A, STAT1, and STAT3 Gene Expressions and TLR2 and TLR4 Molecules in Multiple Sclerosis	6
Meta‐Analysis of Exposure‐Adverse Event Relationships for Antibody–Drug Conjugates	6
Autoimmune Thyroiditis Attenuates Cardiometabolic Effects of Cabergoline in Young Women With Hyperprolactinemia	6
Buprenorphine Continuation During Critical Illness Associated With Decreased Inpatient Opioid Use in Individuals Maintained on Buprenorphine for Opioid Use Disorder in a Retrospective Study	5
Maternal Exposure and Neonatal Effects of Drugs of Abuse	5
Issue Information	5
The New S7B/E14 Question and Answer Draft Guidance for Industry: Contents and Commentary	5
Attempting to Unmask the Inhibition of Sulfotransferase 1E1 in 17α‐Ethinyl Estradiol Drug Interactions	5
Sentinel Dosing—Time for a Risk‐Based Approach?	5
A Retrospective Analysis of Intravenous vs Oral Antibiotic Step‐Down Therapy for the Treatment of Uncomplicated Streptococcal Bloodstream Infections	5
Pharmacokinetics and Pharmacodynamics of GalNAc‐Conjugated siRNAs	5
Biperiden Challenge Model in Healthy Elderly as Proof‐of‐Pharmacology Tool: A Randomized, Placebo‐Controlled Trial	5
Use of Propensity Scoring and Its Application to Real‐World Data: Advantages, Disadvantages, and Methodological Objectives Explained to Researchers Without Using Mathematical Equations	5
Issue Information	5
	5
Comparison of Misoprostol and Evening Primrose Oil on Cervical Preparation Before Gynecological Surgery	5
Characterization of Renal OAT3 and Hepatic CYP3A Activities in Pregnant Women with Acute Pyelonephritis Using the Endogenous Biomarker Cortisol and 6β‐Hydroxycortisol	5
Redefining Statin Dosage Post‐Gastric Bypass: Insights from a Population Pharmacokinetics–Pharmacodynamics Link Approach	5
P‐Glycoprotein and Organic Anion Transporter Polypeptide 1B/Breast Cancer Resistance Protein Drug Transporter Activity in Pregnant Women Living With HIV	5
Effect of Age, Comedications, and CYP3A4/5 Polymorphisms on Perampanel Exposure in Chinese Pediatric Patients With Epilepsy	5
PEG That Reaction: A Case Series of Allergy to Polyethylene Glycol	5
Off‐Label Use of Hydroxychloroquine in COVID‐19: Analysis of Reports of Suspected Adverse Reactions From the Italian National Network of Pharmacovigilance	5
Personalized Dosing of Infliximab in Patients With Inflammatory Bowel Disease Using a Bayesian Approach: A Next Step in Therapeutic Drug Monitoring	5
Issue Information	5
Predicting Human Fetal Drug Exposure Through Maternal‐Fetal PBPK Modeling and In Vitro or Ex Vivo Studies	5
Predict the Drug–Drug Interaction of a Novel PI3Kα/δ Inhibitor, TQ‐B3525, and Its Two Metabolites Using Physiologically Based Pharmacokinetic Modeling	5
In Vitro Evaluation of CYP‐Mediated Metabolism of Fezolinetant and Pharmacokinetic Interaction Between Fezolinetant and Fluvoxamine in Healthy Postmenopausal Smokers and Nonsmokers	5
Population Pharmacokinetic Modeling Combined With Machine Learning Approach Improved Tacrolimus Trough Concentration Prediction in Chinese Adult Liver Transplant Recipients	5

Population Pharmacokinetics of TAK‐931, a Cell Division Cycle 7 Kinase Inhibitor, in Patients With Advanced Solid Tumors	4
	4
Food Effect in Pediatric Populations: Current Practice, Challenges, and Future Potential for Use of Physiologically Based Biopharmaceutics Modeling	4
Assessing Pharmacokinetics in Liver Disease: Challenges and Future Considerations for Classification of Hepatic Dysfunction and Use of In Silico Methods	4
	4
Response to Letter to the Editor by Dr Robinson	4
Renal Impairment in Pediatric Patients: Current Approaches to Drug Dosing	4
Issue Information	4
Model‐Informed Pediatric Drug Development: Application of Pharmacometrics to Define the Right Dose for Children	4
Pediatric Extrapolation Approach for U.S. Food and Drug Administration Approval of Brexpiprazole in Patients Aged 13 to 17 Years with Schizophrenia	4
A Phase 1 Trial to Evaluate the Relationship Between Fluoride Intake and Urinary Fluoride Excretion in Healthy Participants	4
Is There a Need for a Dedicated Pharmacokinetic Trial for a Drug in Obese Populations? A Drug Prioritization Decision Tree Framework	4
Efficacy and Safety of Annual Infusion of Zoledronic Acid and Weekly Oral Alendronate in the Treatment of Primary Osteoporosis: A Meta‐Analysis	4
A Multiple Logistic Regression Model Based on Gamma‐Glutamyl Transferase as a Biomarker for Early Prediction of Drug‐Induced Liver Injury in Vietnamese Patients	4
Population Pharmacokinetic Model of Platinum Disposition in Cancer Patients Receiving Cisplatin and Randomized to 5‐HT3 Antagonist Antiemetic Drugs	4
First‐in‐Human Study of the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of DS‐7011a, an Anti‐TLR7 Antagonistic Monoclonal Antibody for the Treatment of Systemic Lupus	4
Periprocedural Myocardial Injury in High‐Risk Patients With NSTEMI Pretreated With Ticagrelor for Less or More Than 6 Hours Before PCI	4
The Impact of Survival Benefit and Study Design on FDA Approval for Anticancer Drugs Over the Past Decades	4
The New S7B/E14 Q&A Document Provides Additional Opportunities to Replace the Thorough QT Study	4
Response to Letter to the Editor From Dr. Cimolai	4
	4
Population Pharmacokinetics of Patritumab Deruxtecan in Patients With Solid Tumors	4
Could Active Hexose Correlated Compound (AHCC) Currently Be an Appropriate Choice to Clear Human Papillomavirus Infection?	4
Hypertensive Crisis Following COVID‐19 Vaccination	4
Issue Information	4
Comment: Cerebrospinal Fluid Pharmacokinetics of Nicardipine Following Intrathecal Administration in Subarachnoid Hemorrhage Patients	4
Dosing Strategy of Immunoglobulin (IgG) Replacement Therapies in Obese and Overweight Patients with Primary Immunodeficiency Diseases (PIDDs): A Meta‐Analysis of Clinical Trials	4
Pharmacokinetics of JNJ‐73763989 and JNJ‐56136379 (Bersacapavir) in Participants With Moderate Hepatic Impairment	4
Different Kinetics of Activated Clotting Time Among Uninterrupted Oral Anticoagulants During Catheter Ablation Procedure	4
	4
Patient‐Reported Outcomes: Listening for What Is Most Important in Clinical Care and Patient‐Focused Drug Development	4
Investigation of the Effect of Lasmiditan on the Pharmacokinetics of P‐Glycoprotein and Breast Cancer Resistance Protein Substrates	4
Effects of Hepatic Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites	4
Issue Information	4
Population Pharmacokinetics as a Tool to Reevaluate the Complex Disposition of Ethanol in the Fed and Fasted States	3
Novel Patient‐Friendly Orodispersible Formulation of Ivermectin is Associated With Enhanced Palatability, Controlled Absorption, and Less Variability: High Potential for Pediatric Use	3
Overview of Clinical Pharmacology Packages of New Drug Applications Approved for the Treatment of Rare Diseases	3
	3
Dose‐Related Adverse Drug Events in Neonates: Recognition and Assessment	3
Use of Physiologically Based Pharmacokinetic Modeling to Evaluate the Impact of Chronic Kidney Disease on CYP3A4‐Mediated Metabolism of Saxagliptin	3
Population Pharmacokinetics of Ranibizumab Delivered via the Port Delivery System Implanted in the Eye in Patients with Neovascular Age‐Related Macular Degeneration	3
Are Exposure Recommendations for QT Evaluation Being Fulfilled?	3
Off‐Label Use of Ketamine: A Challenging Drug Treatment Delivery Model With an Inherently Unfavorable Risk‐Benefit Profile	3
Issue Information	3
Therapeutic Strategies for Idiopathic Pulmonary Fibrosis – Thriving Present and Promising Tomorrow	3
Evaluation of Hemoglobin Response to Treatment With Enarodustat Using Pharmacometric Approach in Japanese Anemic Patients With Chronic Kidney Disease	3
Mechanistic Framework to Predict Maternal‐Placental‐Fetal Pharmacokinetics of Nifedipine Employing Physiologically Based Pharmacokinetic Modeling Approach	3
Issue Information	3
Ocular Pharmacology	3
	3
Pharmacokinetic and Pharmacodynamic Modeling Analysis of Delpazolid (LCB01‐0371) in Adult Patients with Pulmonary Tuberculosis	3
Combinations of Drug Candidate Properties Affecting Development Success and Discontinuation for 5 Diseases: Lymphoma, Non–Small Cell Lung Cancer, Arthritis, Depression, and Alzheimer Disease	3
Racial and Ethnic Differences in Drug Disposition and Response: Review of New Molecular Entities Approved Between 2014 and 2019	3
Vedolizumab Immunogenicity With Long‐Term or Interrupted Treatment of Patients With Inflammatory Bowel Disease	3
Clinical Pharmacology Profile of AMG 119, the First Chimeric Antigen Receptor T (CAR‐T) Cell Therapy Targeting Delta‐Like Ligand 3 (DLL3), in Patients with Relapsed/Refractory Small Cell Lung Cancer (	3
Drug–Drug Interactions in People Living With HIV at Risk of Hepatic and Renal Impairment: Current Status and Future Perspectives	3
Issue Information	3
Clinical Pharmacology of Electronic Nicotine Delivery Systems (ENDS): Implications for Benefits and Risks in the Promotion of the Combusted Tobacco Endgame	3
Clinical Benefit‐Risk Assessment of Nivolumab 240 mg Every 2 Weeks in Chinese Patients With Advanced and Metastatic Solid Tumors	3
QT Prolongation Risk Assessment in Oncology: Lessons Learned From Small‐Molecule New Drug Applications Approved During 2011‐2019	3
Baricitinib: From Rheumatoid Arthritis to COVID‐19	3
Pharmacokinetics of Ipatasertib in Subjects With Hepatic Impairment Using 2 Methods of Classification of Hepatic Function	3
Issue Information	3
Exposure‐Response Relationships for Pralsetinib in Patients with RET‐Altered Thyroid Cancer or RET Fusion‐Positive Nonsmall Cell Lung Cancer	3
	3
Applying Neural ODEs to Derive a Mechanism‐Based Model for Characterizing Maturation‐Related Serum Creatinine Dynamics in Preterm Newborns	3
Do P‐glycoprotein Medications Alter the Risk of Ventriculoperitoneal Shunt in Adults with Hydrocephalus?	3
Guiding Dyslipidemia Treatment: A Population Pharmacokinetic–Pharmacodynamic Framework for Obicetrapib	3
The Role of the Mesencephalic Astrocyte‐Derived Neurotrophic Factor in Patients in Intensive Care Units Receiving Voriconazole Therapy	3
Clinical Assessment of Fetal Well‐Being and Fetal Safety Indicators	3
Pharmacologic Similarities and Differences Among Hallucinogens	3
The Effect of Hepatic Impairment on the Pharmacokinetics of Intravenously Administered Felcisetrag (TAK‐954)	3
Impact of Pregnancy and Vitamin A Supplementation on CYP2D6 Activity	3
Population Pharmacokinetics of Monalizumab in Patients With Advanced Solid Tumors	3
Association Between Steroid Use and Nephropathy in Patients Who Were Administered a Proton Pump Inhibitor: Analysis of the Japanese Adverse Event Report Database	3
Pooled Population Pharmacokinetic Analyses of Venetoclax in Patients Across Indications and Healthy Subjects from Phase 1, 2, and 3 Clinical Trials	3
Effectiveness and Safety of Histamine H2 Receptor Antagonists: An Umbrella Review of Meta‐Analyses	3
Risk Factors for Angiotension‐Converting Enzyme Inhibitor–Associated Cough	3
Using Real‐World Data to Externally Evaluate Population Pharmacokinetic Models of Dexmedetomidine in Children and Infants	3
A Randomized, Controlled Study to Assess Biomarkers of Exposure in Adult Smokers Switching to Oral Nicotine Products	3
Model‐Informed Dose Justifications of Posaconazole in Japanese Patients for Prophylaxis and Treatment Against Fungal Infection	3
Pharmacokinetics of Tropifexor, a Potent Farnesoid X Receptor Agonist, in Participants With Varying Degrees of Hepatic Impairment	3
Exposure to Macrolides During Pregnancy and the Risk for Spontaneous Abortions: A Population‐Based Retrospective Cohort Study	3
Translating Clinical Pharmacology Data in Pregnancy to Evidence‐Based Guideline Recommendations: Perspectives From the HIV Field	3
Quantitative Assessment of Drug Efficacy and Emergence of Resistance in Patients with Metastatic Renal Cell Carcinoma Using a Longitudinal Exposure‐Tumor Growth Inhibition Model: Apitolisib (Dual PI3K	3
Diagnostic Accuracy of Therapeutic Drug Monitoring During Tuberculosis Treatment	3
Influence of Prednisone on Inflammatory Biomarkers in Community‐Acquired Pneumonia: Secondary Analysis of a Randomized Trial	3
Bisphosphonate Use Is Not Associated With Tuberculosis Risk Among Patients With Osteoporosis: A Nationwide Cohort Study	3
Population Pharmacokinetics and Exposure‐Response Relationships of Astegolimab in Patients With Severe Asthma	3
A Population Pharmacokinetic Meta‐Analysis of Veliparib, a PARP Inhibitor, Across Phase 1/2/3 Trials in Cancer Patients	2
Association Between Exposure to Effervescent Paracetamol and Hospitalization for Acute Heart Failure: A Case‐Crossover Study	2
Development and Evaluation of Ontogeny Functions of the Major UDP‐Glucuronosyltransferase Enzymes to Underwrite Physiologically Based Pharmacokinetic Modeling in Pediatric Populations	2
Isoniazid Population Pharmacokinetics and Dose Recommendation for Korean Patients With Tuberculosis Based on Target Attainment Analysis	2
Anaphylaxis and Related Events Following COVID‐19 Vaccination: A Systematic Review	2
Population Pharmacokinetic Analysis of Brexpiprazole to Support its Indication and Dose Selection in Adolescents With Schizophrenia	2